Melanotan 2 tanning and sunlight
The original ambition was protection from sunlight. The strongest human evidence for that ambition accumulated around a different molecule.
Tanning without UV exposure
The Melanotan II pigmentation pilot enrolled three healthy men. Two developed greater pigmentation of the face, upper body and buttocks after five exposures over two weeks, without UV exposure. Spontaneous erections and mild nausea accompanied the skin response.
The elegance appeals to me. A tan without the usual sunlight sounds like an elegant way around a familiar injury. The study demonstrated pigmentation; it had no completed long-term programme establishing cancer prevention or safe cosmetic use.
Melanotan II activates pigment-making cells through melanocortin signalling. The mechanism page follows that activity inside the cell. Colour, however, is only one possible endpoint for a sunlight study.
The skin-biopsy experiment used Melanotan 1
In the human eumelanin experiment, seven volunteers received Melanotan 1. Analysis of skin biopsies found roughly a 49% rise in forehead eumelanin and 98% in forearm eumelanin one week after dosing, without a significant change in pheomelanin. Eumelanin is the brown-black pigment with a photoprotective role.
I wish every retelling of these results carried the drug’s name along with them. The analysis measured pigment chemically, which is more informative than judging a photograph. Its subject was the linear analogue Melanotan 1, also called afamelanotide. Those percentages cannot describe Melanotan 2.
Afamelanotide and painful sunlight exposure
Erythropoietic protoporphyria, or EPP, makes brief sunlight exposure painfully difficult. The two placebo-controlled Phase 3 afamelanotide trials found longer pain-free sun exposure and fewer phototoxic reactions. That programme led to approval for afamelanotide in EPP.
The observational follow-up of 115 patients reported sustained quality-of-life improvement and mainly minor adverse events, predominantly nausea. I consider time outdoors without pain a more meaningful outcome than a shade change. It is also an outcome studied in a specific illness with a separate medicine.
Melanotan 2 has no approved use. Afamelanotide’s approval and follow-up apply to afamelanotide; the similar family names create no shared permission.
Moles and claims of protection
The review of unregulated melanotropic products discusses both the pursuit of a UV-free tan and the resulting public-health concerns. Published reports describe new or darkened moles and melanoma associated with use. The long-term causal risk remains unresolved.
Some online accounts treat deeper colour as permission for more sun; others describe burning despite the tan. Those are anecdotal beliefs and experiences, not clinical evidence of protection. I doubt the advertised shortcut more after these reports. Its promise has run far ahead of the human Melanotan II record.